GI Drugs Cmte. To Weigh Retreatment Study Design For Salix's Xifaxan In Irritable Bowel

On Nov. 16, FDA's outside advisors will discuss the design of clinical trials to evaluate the safety, efficacy and durability of response with repeat treatment cycles of rifaximin for diarrhea-predominant IBS.